Elysium Health and the Supplement Basis

February 1, 2018
By Rel

Elysium Health is a company producing evidence-based dietary supplements that is based in New York City, New York. Dr. Leonard Guarente, Eric Marcotulli, and Dan Alminana founded the company in 2014, launching the supplement Basis just a few months after, in early 2015.

Currently, Guarente is the company’s chief scientist, Marcotulli is Elysium Health’s CEO, and Alminana is its COO. Basis remains the sole supplement under production at Elysium Health, although the company is currently in the process of developing other supplements to better serve cognitive, skin, and general cellular health.

Basis is a Leading Supplement for Cellular Health

Elysium Health’s supplement Basis combines nicotinamide riboside and pterostilbene, two compounds proven to boost levels of NAD+ in our cells.

In the first few months of 2016, a clinical trial for repeat dose of nicotinamide riboside and pterostilbene were initiated. The trials involved a group of 40 participants receiving 250 the recommended daily dose of Basis, a group of 40 participants receiving twice the daily dose of the supplement, and a group of 40 participants receiving a placebo. All were between ages 60 and 80 years.

The results of the clinical trial, published in November 2017 in the academic journal npj: Aging and Mechanisms of Disease, demonstrated that within four weeks, participants taking the recommended daily dose of Basis experienced on average a 40 percent increase in NAD+ levels. The second group, participants taking twice the recommended daily dose, experienced on average a 90 percent increase in NAD+ levels. The third group, the placebo group, did not experience an increase in NAD+ levels. The increases in NAD+ levels were sustained throughout the duration of the trial.

The Role of Basis in Boosting Quality of Life in Consumers

One of the many effects of aging is a natural decrease in NAD+ levels. But NAD+ is essential to many cellular functions like circadian rhythms and DNA maintenance. That is why Basis seeks to increase levels of NAD+ in humans, supporting cellular well-being as a result.